<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This article describes the pharmacological properties and the overall preclinical and clinical profiling of <z:chebi fb="0" ids="51450">bosentan</z:chebi> (Ro 47-0203), a non-<z:chebi fb="7" ids="16670">peptide</z:chebi> <z:chebi fb="0" ids="51451">endothelin receptor antagonist</z:chebi> with oral activity </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="51450">Bosentan</z:chebi> is a combined and competitive <z:chebi fb="68" ids="48706">antagonist</z:chebi> of both <z:chebi fb="209" ids="16000,53460">ETA</z:chebi> and ETB receptors that is selective for the endothelin system </plain></SENT>
<SENT sid="2" pm="."><plain>In vitro and in vivo, <z:chebi fb="0" ids="51450">bosentan</z:chebi> potently antagonises the vascular response elicited by the endothelins </plain></SENT>
<SENT sid="3" pm="."><plain>Preclinical efficacy is demonstrated in a variety of pathological models including pulmonary and essential <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0000083'>renal failure</z:hpo> of ischaemic and nephrotic origin and <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> following <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Effects are particularly marked in experimental models of <z:hpo ids='HP_0001635'>heart failure</z:hpo> (HF) where <z:chebi fb="0" ids="51450">bosentan</z:chebi> acts as a potent <z:chebi fb="1" ids="35620">vasodilator</z:chebi> that improves overall left ventricular performance </plain></SENT>
<SENT sid="5" pm="."><plain>After <z:hpo ids='HP_0011010'>chronic</z:hpo> treatment, <z:chebi fb="0" ids="51450">bosentan</z:chebi> also improves survival in rats with HF </plain></SENT>
<SENT sid="6" pm="."><plain>As a result of the first encouraging clinical results that show pulmonary and systemic vasodilation, long-term studies are ongoing in the treatment of <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) </plain></SENT>
</text></document>